Pharmacovigilance Automation

Published on: 
BioPharm International, BioPharm International Quality and Regulatory Sourcebook 2023, Volume 2023 eBook, Issue 1
Pages: 7-9

Organizations can better understand the maturity of AI-driven automation technology across their organization’s IT landscape through effective pharmacovigilance.

A safety surveillance strategy is a requirement for pharmaceutical companies to monitor product safety in the post-marketing environment, as well as to keep physicians informed on product risks and how to prescribe appropriately. This is usually seen as a labor-intensive cost center that often overburdens teams with work, making it difficult to retain talent. As the industry becomes more cost-conscious and is handling more real-world data sources than ever, companies are seeking ways to improve the efficiency and effectiveness of their pharmacovigilance (PV) activities. Automation offers the solution for organizations prepared to embrace it and to do the hard work required to support digital transformation.


Why automation is vital in pharmacovigilance

Many reasons exist to support the adoption of automation in drug safety surveillance. Using artificial intelligence (AI) in safety surveillance can automate many aspects of the process, including non-electronic data collection, processing of inbound data, and triaging data according to its source. With these applications, companies can increase productivity, lower their technology costs, and reduce their reliance on manual labor.

Read this article in the Quality and Regulatory Sourcebook 2023

About the author

Updesh Dosanjh is a practice leader for technology solutions at IQVIA.

Article details

BioPharm International
eBook: Quality and Regulatory

March 2023
Pages: 7-9


When referring to this article, please cite it as U. Dosanjh, "Pharmacovigilance Automation," BioPharm International's Quality and Regulatory eBook (March 2023).